Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

5.340 -0.150 (-2.73%)
Streaming Delayed Price Updated: 10:07 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Regencell, Beyond Meat, Alvotech, and Camping World and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
From Alvotech
Via GlobeNewswire
News headline image
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
News headline image
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
From Alvotech
Via GlobeNewswire
News headline image
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Alvotech INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (ALVO)
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
From Alvotech
Via GlobeNewswire
News headline image
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
From Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma
Via Business Wire
News headline image
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
From Alvotech
Via GlobeNewswire
News headline image
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
News headline image
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
From Alvotech
Via GlobeNewswire
News headline image
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
From Alvotech
Via GlobeNewswire
News headline image
Main Results of 2025 Annual and Extraordinary General Meeting
From Alvotech
Via GlobeNewswire
News headline image
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
News headline image
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.